WASHINGTON DC (January 7, 2020) – Today Katherine Michelle Raab is joining the Association for Accessible Medicines (AAM). As a senior strategist and lobbyist, she represents AAM and its member companies’ interests before Congress and the White House. In this role she develops short- and long-term goals in support of the federal affairs strategy and leads the promotion of AAM’s objectives through advocacy while preserving and enhancing the association’s important relationships on Capitol Hill.
Previously, Katherine was vice president at the Nickles Group, where she represented a variety of health care clients, including established and emerging biopharmaceutical companies. From 2008 to 2017, she served as director of federal government affairs for Genentech. Earlier in her career, Katherine worked in the U.S. House of Representatives’ Counsel for Health Subcommittee and on the legislative staff of three representatives. She earned her MBA from Johns Hopkins and her BA from the University of Richmond.
“Katherine will bring a wealth of advocacy and policy expertise to our team at an important time in the national discussion about lowering the cost of prescription drugs,” said Chris Bowlin, AAM Senior Vice President, Government Affairs. “We are fortunate to have someone with her background and skill set helping advance the priorities of the generic and biosimilars sectors before Congress.”
MEDIA CONTACT:
Rachel Schwartz
202.249.7147
About AAM
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 22 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.